AC Immune (NASDAQ:ACIU) Stock Price Down 1.3% – Should You Sell?

Shares of AC Immune (NASDAQ:ACIU) fell 1.3% during mid-day trading on Wednesday . The stock traded as low as $2.20 and last traded at $2.27. Approximately 245,506 shares traded hands during mid-day trading, a decline of 4% from the average session volume of 255,854 shares. The stock had previously closed at $2.30.

Analyst Upgrades and Downgrades

Several analysts recently commented on ACIU shares. Weiss Ratings lowered AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. HC Wainwright reissued a “buy” rating on shares of AC Immune in a report on Wednesday, July 1st. Finally, BTIG Research restated a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research report on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $7.50.

AC Immune Stock Performance

The business’s fifty day moving average is $2.49 and its two-hundred day moving average is $2.87. The stock has a market capitalization of $231.02 million, a PE ratio of -2.77 and a beta of 1.57. The company has a quick ratio of 1.02, a current ratio of 0.87 and a debt-to-equity ratio of 0.11.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. The business had revenue of $1.40 million during the quarter, compared to analyst estimates of $0.33 million. As a group, research analysts anticipate that AC Immune will post -0.84 EPS for the current fiscal year.

Insider Buying and Selling at AC Immune

In other news, CEO Andrea Pfeifer sold 10,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $2.79, for a total transaction of $27,900.00. Following the sale, the chief executive officer directly owned 3,820,288 shares in the company, valued at approximately $10,658,603.52. This represents a 0.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACIU. Arrowstreet Capital Limited Partnership raised its position in AC Immune by 8.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after purchasing an additional 30,035 shares during the period. Dimensional Fund Advisors LP increased its position in AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after acquiring an additional 176,701 shares during the last quarter. EFG International AG purchased a new stake in shares of AC Immune in the fourth quarter valued at $41,000. Marshall Wace LLP bought a new stake in shares of AC Immune in the 4th quarter worth about $586,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of AC Immune by 46.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after purchasing an additional 5,920 shares during the period. Hedge funds and other institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.